"As these products that incorporate nanotechnology move into the market, there needs to be a lot more money invested in agencies such as the FDA and EPA — they are radically underfunded."

— David Rejeski of the Project on Emerging Nanotechnologies, "Lack of resources means nano risk assessment falling short," pp. 1, 6.